Table of Content

1 Adalimumab Monoclonal Antibody Biosimilar Market Overview
1.1 Product Overview and Scope of Adalimumab Monoclonal Antibody Biosimilar
1.2 Adalimumab Monoclonal Antibody Biosimilar Segment by Type
1.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2024-2034)
1.2.2 Syringe
1.2.3 Pen
1.3 Adalimumab Monoclonal Antibody Biosimilar Segment by Application
1.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Value by Application: (2024-2034)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue 2018-2034
1.4.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales 2018-2034
1.4.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Adalimumab Monoclonal Antibody Biosimilar Market Competition by Manufacturers
2.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Adalimumab Monoclonal Antibody Biosimilar Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Product Type & Application
2.7 Adalimumab Monoclonal Antibody Biosimilar Market Competitive Situation and Trends
2.7.1 Adalimumab Monoclonal Antibody Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adalimumab Monoclonal Antibody Biosimilar Players Market Share by Revenue
2.7.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adalimumab Monoclonal Antibody Biosimilar Retrospective Market Scenario by Region
3.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Adalimumab Monoclonal Antibody Biosimilar Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2018-2034
3.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2018-2023
3.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2024-2034
3.3 Global Adalimumab Monoclonal Antibody Biosimilar Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018-2034
3.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2024-2034
3.4 North America Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.4.1 North America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
3.4.3 North America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.5.1 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
3.5.3 Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
3.6.3 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
3.7.3 Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
3.8.3 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2034)
4.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023)
4.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034)
4.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
4.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2034)
4.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034)
4.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
4.3 Global Adalimumab Monoclonal Antibody Biosimilar Price by Type (2018-2034)
5 Segment by Application
5.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2034)
5.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023)
5.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034)
5.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
5.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2034)
5.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034)
5.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
5.3 Global Adalimumab Monoclonal Antibody Biosimilar Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Cadila Healthcare
6.1.1 Cadila Healthcare Corporation Information
6.1.2 Cadila Healthcare Description and Business Overview
6.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.1.5 Cadila Healthcare Recent Developments/Updates
6.2 Torrent Pharmaceuticals
6.2.1 Torrent Pharmaceuticals Corporation Information
6.2.2 Torrent Pharmaceuticals Description and Business Overview
6.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.2.5 Torrent Pharmaceuticals Recent Developments/Updates
6.3 Amgen
6.3.1 Amgen Corporation Information
6.3.2 Amgen Description and Business Overview
6.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.3.5 Amgen Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Corporation Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Corporation Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Viatris
6.6.1 Viatris Corporation Information
6.6.2 Viatris Description and Business Overview
6.6.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.7.5 Viatris Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Fresenius Kabi
6.9.1 Fresenius Kabi Corporation Information
6.9.2 Fresenius Kabi Description and Business Overview
6.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.9.5 Fresenius Kabi Recent Developments/Updates
6.10 Coherus
6.10.1 Coherus Corporation Information
6.10.2 Coherus Description and Business Overview
6.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.10.5 Coherus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab Monoclonal Antibody Biosimilar Industry Chain Analysis
7.2 Adalimumab Monoclonal Antibody Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab Monoclonal Antibody Biosimilar Production Mode & Process
7.4 Adalimumab Monoclonal Antibody Biosimilar Sales and Marketing
7.4.1 Adalimumab Monoclonal Antibody Biosimilar Sales Channels
7.4.2 Adalimumab Monoclonal Antibody Biosimilar Distributors
7.5 Adalimumab Monoclonal Antibody Biosimilar Customers
8 Adalimumab Monoclonal Antibody Biosimilar Market Dynamics
8.1 Adalimumab Monoclonal Antibody Biosimilar Industry Trends
8.2 Adalimumab Monoclonal Antibody Biosimilar Market Drivers
8.3 Adalimumab Monoclonal Antibody Biosimilar Market Challenges
8.4 Adalimumab Monoclonal Antibody Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Adalimumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Adalimumab Monoclonal Antibody Biosimilar Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Adalimumab Monoclonal Antibody Biosimilar Market Competitive Situation by Manufacturers in 2024
Table 4. Global Adalimumab Monoclonal Antibody Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Adalimumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Adalimumab Monoclonal Antibody Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Adalimumab Monoclonal Antibody Biosimilar, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Product Type & Application
Table 12. Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Adalimumab Monoclonal Antibody Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab Monoclonal Antibody Biosimilar as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2018-2023) & (K Units)
Table 18. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2018-2023)
Table 19. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2024-2034) & (K Units)
Table 20. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2024-2034)
Table 21. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2018-2023)
Table 23. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2024-2034)
Table 25. North America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 27. North America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 28. North America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 32. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 33. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Adalimumab Monoclonal Antibody Biosimilar Sales (K Units) by Type (2018-2023)
Table 51. Global Adalimumab Monoclonal Antibody Biosimilar Sales (K Units) by Type (2024-2034)
Table 52. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2023)
Table 53. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2024-2034)
Table 54. Global Adalimumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Adalimumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2023)
Table 57. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2024-2034)
Table 58. Global Adalimumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Type (2018-2023)
Table 59. Global Adalimumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Type (2024-2034)
Table 60. Global Adalimumab Monoclonal Antibody Biosimilar Sales (K Units) by Application (2018-2023)
Table 61. Global Adalimumab Monoclonal Antibody Biosimilar Sales (K Units) by Application (2024-2034)
Table 62. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2023)
Table 63. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2024-2034)
Table 64. Global Adalimumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Adalimumab Monoclonal Antibody Biosimilar Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2023)
Table 67. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2024-2034)
Table 68. Global Adalimumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Application (2018-2023)
Table 69. Global Adalimumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Application (2024-2034)
Table 70. Cadila Healthcare Corporation Information
Table 71. Cadila Healthcare Description and Business Overview
Table 72. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product
Table 74. Cadila Healthcare Recent Developments/Updates
Table 75. Torrent Pharmaceuticals Corporation Information
Table 76. Torrent Pharmaceuticals Description and Business Overview
Table 77. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product
Table 79. Torrent Pharmaceuticals Recent Developments/Updates
Table 80. Amgen Corporation Information
Table 81. Amgen Description and Business Overview
Table 82. Amgen Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Amgen Adalimumab Monoclonal Antibody Biosimilar Product
Table 84. Amgen Recent Developments/Updates
Table 85. Boehringer Ingelheim Corporation Information
Table 86. Boehringer Ingelheim Description and Business Overview
Table 87. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product
Table 89. Boehringer Ingelheim Recent Developments/Updates
Table 90. Novartis Corporation Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Novartis Adalimumab Monoclonal Antibody Biosimilar Product
Table 94. Novartis Recent Developments/Updates
Table 95. Samsung Bioepis Corporation Information
Table 96. Samsung Bioepis Description and Business Overview
Table 97. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product
Table 99. Samsung Bioepis Recent Developments/Updates
Table 100. Viatris Corporation Information
Table 101. Viatris Description and Business Overview
Table 102. Viatris Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Viatris Adalimumab Monoclonal Antibody Biosimilar Product
Table 104. Viatris Recent Developments/Updates
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Pfizer Adalimumab Monoclonal Antibody Biosimilar Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Fresenius Kabi Corporation Information
Table 111. Fresenius Kabi Description and Business Overview
Table 112. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product
Table 114. Fresenius Kabi Recent Developments/Updates
Table 115. Coherus Corporation Information
Table 116. Coherus Description and Business Overview
Table 117. Coherus Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Coherus Adalimumab Monoclonal Antibody Biosimilar Product
Table 119. Coherus Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Adalimumab Monoclonal Antibody Biosimilar Distributors List
Table 123. Adalimumab Monoclonal Antibody Biosimilar Customers List
Table 124. Adalimumab Monoclonal Antibody Biosimilar Market Trends
Table 125. Adalimumab Monoclonal Antibody Biosimilar Market Drivers
Table 126. Adalimumab Monoclonal Antibody Biosimilar Market Challenges
Table 127. Adalimumab Monoclonal Antibody Biosimilar Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Adalimumab Monoclonal Antibody Biosimilar
Figure 2. Global Adalimumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Type in 2024 & 2034
Figure 4. Syringe Product Picture
Figure 5. Pen Product Picture
Figure 6. Global Adalimumab Monoclonal Antibody Biosimilar Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Application in 2024 & 2034
Figure 8. Ankylosing Spondylitis
Figure 9. Rheumatoid Arthritis
Figure 10. Crohn’s Disease
Figure 11. Other
Figure 12. Global Adalimumab Monoclonal Antibody Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Adalimumab Monoclonal Antibody Biosimilar Market Size (2018-2034) & (US$ Million)
Figure 14. Global Adalimumab Monoclonal Antibody Biosimilar Sales (2018-2034) & (K Units)
Figure 15. Global Adalimumab Monoclonal Antibody Biosimilar Average Price (US$/Unit) & (2018-2034)
Figure 16. Adalimumab Monoclonal Antibody Biosimilar Report Years Considered
Figure 17. Adalimumab Monoclonal Antibody Biosimilar Sales Share by Manufacturers in 2024
Figure 18. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Manufacturers in 2024
Figure 19. The Global 5 and 10 Largest Adalimumab Monoclonal Antibody Biosimilar Players: Market Share by Revenue in 2024
Figure 20. Adalimumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 21. Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 22. North America Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2018-2034)
Figure 23. North America Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2018-2034)
Figure 24. United States Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Canada Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2018-2034)
Figure 27. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2018-2034)
Figure 28. Germany Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. France Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. U.K. Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Italy Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Russia Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2018-2034)
Figure 34. Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2018-2034)
Figure 35. China Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Japan Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. South Korea Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. India Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Australia Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. China Taiwan Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Southeast Asia Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Latin America Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2018-2034)
Figure 43. Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2018-2034)
Figure 44. Mexico Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Brazil Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Argentina Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Colombia Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2018-2034)
Figure 49. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2018-2034)
Figure 50. Turkey Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Saudi Arabia Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. UAE Adalimumab Monoclonal Antibody Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Global Sales Market Share of Adalimumab Monoclonal Antibody Biosimilar by Type (2018-2034)
Figure 54. Global Revenue Market Share of Adalimumab Monoclonal Antibody Biosimilar by Type (2018-2034)
Figure 55. Global Adalimumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Type (2018-2034)
Figure 56. Global Sales Market Share of Adalimumab Monoclonal Antibody Biosimilar by Application (2018-2034)
Figure 57. Global Revenue Market Share of Adalimumab Monoclonal Antibody Biosimilar by Application (2018-2034)
Figure 58. Global Adalimumab Monoclonal Antibody Biosimilar Price (US$/Unit) by Application (2018-2034)
Figure 59. Adalimumab Monoclonal Antibody Biosimilar Value Chain
Figure 60. Adalimumab Monoclonal Antibody Biosimilar Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed